TY - JOUR
T1 - Modern treatment to reduce pulmonary arterial pressure in pulmonary arterial hypertension
AU - Akagi, Satoshi
AU - Matsubara, Hiromi
AU - Nakamura, Kazufumi
AU - Ito, Hiroshi
N1 - Funding Information:
H. Matsubara has received lecture fees from Actelion Pharmaceuticals Japan, AOP Orphan Pharmaceuticals, Bayer Yakuhin, GlaxoSmithKline, Nippon Shinyaku, and Pfizer Japan, and a research grant from Nippon Shinyaku.
Funding Information:
H. Ito has received lecture fees from Mochida Pharmaceutical and a research grant from Mochida Pharmaceutical, Actelion Pharmaceuticals Japan, AOP Orphan Pharmaceuticals, Bayer Yakuhin, and Nippon Shinyaku.
PY - 2018/12
Y1 - 2018/12
N2 - Treatment goals in pulmonary arterial hypertension (PAH) include improved quality of life and exercise capacity as well as improved life prognosis. In our experience, only remarkable reductions in pulmonary arterial pressure (PAP) improve long-term survival. Lowering PAP could contribute to reverse remodeling by reducing hemodynamic stress. Proper and prompt use of PAH-specific drugs lowers PAP in patients with PAH. Upfront combination therapy with different PAH-specific drugs and quickly establishing high-dose epoprostenol lowers PAP sufficiently to improve prognosis in patients with PAH. PAH is often a comorbidity with other diseases including congenital heart defect, connective tissue diseases, and pulmonary arterial aneurysm. It is essential in these conditions to lower PAP to allow the next treatment strategy. In this report, we review modern treatments to lower PAP in patients with PAH.
AB - Treatment goals in pulmonary arterial hypertension (PAH) include improved quality of life and exercise capacity as well as improved life prognosis. In our experience, only remarkable reductions in pulmonary arterial pressure (PAP) improve long-term survival. Lowering PAP could contribute to reverse remodeling by reducing hemodynamic stress. Proper and prompt use of PAH-specific drugs lowers PAP in patients with PAH. Upfront combination therapy with different PAH-specific drugs and quickly establishing high-dose epoprostenol lowers PAP sufficiently to improve prognosis in patients with PAH. PAH is often a comorbidity with other diseases including congenital heart defect, connective tissue diseases, and pulmonary arterial aneurysm. It is essential in these conditions to lower PAP to allow the next treatment strategy. In this report, we review modern treatments to lower PAP in patients with PAH.
KW - Combination therapy
KW - Lowering pulmonary artery pressure
KW - Pulmonary arterial hypertension
KW - Quickly establishing high-dose epoprostenol therapy
UR - http://www.scopus.com/inward/record.url?scp=85048558206&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048558206&partnerID=8YFLogxK
U2 - 10.1016/j.jjcc.2018.04.014
DO - 10.1016/j.jjcc.2018.04.014
M3 - Review article
C2 - 29898864
AN - SCOPUS:85048558206
VL - 72
SP - 466
EP - 472
JO - Journal of Cardiology
JF - Journal of Cardiology
SN - 0914-5087
IS - 6
ER -